Defying convention.
As leaders in the life sciences, our Directors share our vision for the potential of Synthetic Biotic medicines and challenge us daily to achieve more to advance our mission. Having served at the helm of biotechnology companies and investment firms, our Directors serve as strategic partners and advisors guiding us to achieve progress for patients and the field.
Peter Barrett, PhD
Chairman, Partner, Atlas Venture
Peter Barrett, PhD
Peter is currently chairman of Zafgen (NASDAQ:ZFGN), Synlogic (NASDAQ:SYBX), Cadent Therapeutics and Obsidian Therapeutics, and also serves on the board of Indalo Therapeutics. He previously served on the boards of past Atlas companies Vitae Pharmaceuticals (NASDAQ:VTAE; acquired by Allergan), Stromedix (acquired by Biogen), Novamed (acquired by Sciclone), Alnylam (NASDAQ:ALNY), Harbour Antibodies (acquired by Harbour Biomed), Momenta (NASDAQ:MNTA), Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), Infacare (acquired by Mallinckrodt), Archemix (acquired by Baxter) and a number of other ventures.
Prior to joining Atlas Peter was co-founder, executive vice president, and chief business officer of Celera Genomics, which announced the first successful sequencing of the human genome in 2001. While at Celera, Peter led strategic alliances, acquisitions, and business strategy and helped launch it as a public company in 1999.
Prior to founding Celera, Peter held senior management positions at Applera, most recently serving as vice president of corporate planning and business development. During his tenure, he ran several businesses and expanded the life science business through a series of licensing agreements, partnerships, and acquisitions.
Peter is a member of the research council at Boston Children’s Hospital, and serves on the board of Perkin Elmer (NYSE:PKI).
Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program.
Aoife Brennan, MB, BCh, BAO, MRCPI
President and Chief Executive Officer
Aoife Brennan, MB, BCh, BAO, MRCPI
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.
Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until it’s acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.
Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Mike Burgess, MB, ChB, PhD
President, Research & Development, Turnstone Biologics
Mike Burgess, MB, ChB, PhD
Chau Q. Khuong
Partner, Orbimed Advisors
Chau Q. Khuong
Nick Leschly
CEO, bluebird bio
Nick Leschly
Prior to joining Third Rock, Nick worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product leader for VELCADE.
Nick received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO).
Ed Mathers
Partner, New Enterprise Associates
Ed Mathers
Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor’s degree in chemistry from North Carolina State University.
Richard P. Shea
CFO, Syndax Pharmaceuticals
Richard P. Shea
Patricia N. Hurter, PHD
CEO, Lyndra Therapeutics
Patricia N. Hurter, PhD
A respected thought leader in the pharmaceutical industry, Dr. Hurter is a frequent contributor to many scientific publications. She serves on the Vertex Research & Development and Operating Committees and is the founder and executive sponsor of “IWILL,” a Vertex employee network devoted to the advancement of women leaders. Dr. Hurter also serves as a member of the Board of Trustees of the Harvard Conservation Trust. She holds a Ph.D. in chemical engineering from the Massachusetts Institute of Technology, an M.S. in mechanical engineering from West Virginia University and earned a B.Sc. in chemical engineering, cum laude, from the University of KwaZulu-Natal in Durban, South Africa.